Latest / ESWI Airborne's Podcast / The Two-Way Street: When Respiratory Viruses Meet Chronic Illness
Transcript
- 0:01ESWI Secretariat: Welcome to ESWI Airborne and our special episode on the Interdisciplinary Disease Collaboration on Respiratory Infections and Noncommunicable Diseases, otherwise known as the IDC.
- 0:13ESWI Secretariat: It explores the bidirectional interplay between respiratory viruses and chronic illnesses.
- 0:19ESWI Secretariat: This podcast is made possible thanks to the kind support of Sanofi Pasteur and IFPMA, the International Federation of Pharmaceutical Manufacturers and Association.
- 0:54Jane Barratt (Host): Welcome to ESWI Airborne the podcast of the European Scientific Working Group on Influenza. I'm Jane Barrett and it's a pleasure to host today's conversation.
- 0:58Jane Barratt (Host): Today we turn our attention to the Interdisciplinary Disease Collaboration on Respiratory Infections and NCDs, known as the IDC.
- 1:10Jane Barratt (Host): What began in 2017 as the influenza diabetes community has grown into a broad collaboration connecting scientific societies, patient organisations, clinicians, ministries, researchers, and industry partners.
- 1:28Jane Barratt (Host): The IDC brings together nearly 25 organisations with one single purpose to protect people living with chronic conditions from the serious risks of respiratory virus infections.
- 1:44Jane Barratt (Host): This is indeed a pivotal moment for the IDC.
- 1:48Jane Barratt (Host): We now have a clearer, mechanistic and clinical evidence moving from long-standing observational links to a deeper understanding of causality.
- 1:59Jane Barratt (Host): This shift is reshaping how we think about prevention and risk.
- 2:05Jane Barratt (Host): Let me introduce our guests.
- 2:08Jane Barratt (Host): Dr.
- 2:09Jane Barratt (Host): Marco Goeijenbier is an intensivist at Spaarne Hospital and a senior scientist at Erasmus MC.
- 2:17Jane Barratt (Host): His work spans acute care, infectious diseases, and the intersection of viral infections with coagulation and severe respiratory illness.
- 2:27Jane Barratt (Host): He has been a part of ESWI since 2016 and now serves as IDC co-chair.
- 2:35Jane Barratt (Host): Second, Dr.
- 2:38Jane Barratt (Host): Tor Biering- Sørensen is a cardiologist and the founding head of the Center for Translational Cardiology and Pragmatic Randomised Trials in Copenhagen.
- 2:49Jane Barratt (Host): His research group leads world-class work on cardiovascular imaging, heart failure, infection-related cardiac outcomes, and large-scale pragmatic trials.
- 3:02Jane Barratt (Host): Tor joined Marco as IDC co-chair in 2025.
- 3:08Jane Barratt (Host): Welcome, gentlemen.
- 3:11Jane Barratt (Host): It's good to have you with us today.
- 3:13Marco Goeijenbier: Thank you very much, Jane.
- 3:14Tor Biering- Sørensen: Thank you so much for having us.
- 3:16Jane Barratt (Host): Marco, the IDC began as an influenza diabetes community in 2017, and it's now this incredibly interdisciplinary collaboration spanning infectious diseases, etc.
- 3:30Jane Barratt (Host): What's the history of this organisation and what are the scientific and clinical and societal forces that made this so necessary today?
- 3:42Marco Goeijenbier: Yeah, well, Jane, that's actually quite a long story.
- 3:45Marco Goeijenbier: I think we have about half an hour here, but no, I'll try to be brief.
- 3:48Marco Goeijenbier: So we started this influenza diabetes community simply because there was a strong association between severe respiratory infection or severe influenza for persons living with diabetes.
- 4:00Marco Goeijenbier: And that evidence mainly came from from observational studies and we really wanted to add justice there to this link.
- 4:09Marco Goeijenbier: So we started this influenza diabetes community really working from beds to bed side, so a translational approach with both core scientists, clinicians, but also patient representatives, nurses, alliances, and so on, all with the goal to actually increase vaccine coverage within this specific risk group.
- 4:32Marco Goeijenbier: And while we did quite some interesting projects there, what we actually also saw is that there's just as much evidence in other non-communicable diseases, other risk factors, where we could also actually learn from.
- 4:46Marco Goeijenbier: So the switch was slowly made to broaden our vision.
- 4:52Marco Goeijenbier: And actually it was at the last ESWI in Valencia, we sat together with the whole board and the whole IDC to see how we can actually increase the reach of IDC and increase our scope towards a broader view.
- 5:06Marco Goeijenbier: Also, because more lately, and especially since the pandemic, there's indeed more and more evidence showing a better understanding of why these specific groups have an increased risk of a severe cause of disease, but also the other way around.
- 5:22Marco Goeijenbier: It's a bi-directional relationship, also the effect these infections could have on your underlying chronic condition.
- 5:29Marco Goeijenbier: I think some of the work that actually helps us really showing the evidence that certain risk groups really have an advantage at being vaccinated comes from the group of Tor of all the great work Tor is currently doing.
- 5:45Jane Barratt (Host): Well, that then leads into Tor.
- 5:47Jane Barratt (Host): Tor, you and I have been at several different meetings together, and it's quite interesting, you know, your discipline sitting in a meeting in gerontology, for example, and geriatrics.
- 5:58Jane Barratt (Host): So, what's so important about bringing disciplines together right at this moment in time?
- 6:05Tor Biering- Sørensen: I think, Marco scoped it quite well.
- 6:09Tor Biering- Sørensen: the knowledge about this interplay between all of these many diseases and how they both increase the risk of getting severe infections and also the other way around, right?
- 6:24Tor Biering- Sørensen: How infections cause many of these diseases or make these diseases more severe.
- 6:32Tor Biering- Sørensen: And I think over the last couple of decades, this has become more and more obvious.
- 6:40Tor Biering- Sørensen: The COVID pandemic, of course, also got all disciplines to research an infectious disease, which also made the attention to this association between infections and other diseases much more clear and pushed all specialities into doing research on their own patients and infections.
- 7:02Tor Biering- Sørensen: So I think now we have a unique opportunity to leverage that big interest which the pandemic unfortunately created for all of these specialities to get awareness about the importance of preventing infections now to broaden the scope and tell our own specialty groups that this is actually something that we and Marco's team in ESWI has been promoting and telling everyone for years what downstream risks actually come.
- 7:42Tor Biering- Sørensen: So I think we have a unique opportunity now to spread the word, spread the importance of vaccinations, spread the importance of preventing infections, both within each of our high-risk groups that we have in many of these specialities, regardless whether you're a cardiologist, a gastroenterologist, a diabetologist, to prevent them from getting severe infections, because we know they are increased risk in these high-risk groups, but also to underscore the importance of preventing infections for these out downstream events that we see are much more prevalent if you get a severe infection.
- 8:18Tor Biering- Sørensen: So leveraging this awareness is extremely important to increase vaccine uptake and to increase the prevention of these infections.
- 8:29Marco Goeijenbier: I think you really tell an important message there, Tor.
- 8:33Marco Goeijenbier: Of course, during the pandemic, everybody became a virologist, which makes it really easy to work in virology afterwards.
- 8:40Marco Goeijenbier: But I think that the biggest thing there, what you mentioned, is actually that that all the medical specialties now see what a severe respiratory virus infection effect can have on their patient groups, either if it's cardiovascular or neurological or endocrinology and so on.
- 8:59Jane Barratt (Host): I just wanted to dig a little bit deeper because we know now that respiratory viruses don't operate in isolation, do they?
- 9:07Jane Barratt (Host): And we are really talking about influenza and COVID and RSV and the intersection with diabetes and cardiovascular conditions and other conditions.
- 9:18Jane Barratt (Host): You know, Tor, I want to just hear a little bit more about, you know, the pragmatic randomized trials that you've been undertaking.
- 9:26Jane Barratt (Host): And, you know, try and understand what you have been doing with your team in unpacking this intersection between respiratory conditions and NCDs.
- 9:40Tor Biering- Sørensen: Yeah, it's been quite an adventure the last couple of years because we have tried to do, as Marco mentioned in the introduction, a lot of the information that we have putting these links together, you know, the increased risk of from my topic, cardiovascular diseases, the increased risk of of cardiovascular events when you have an infection, they are mainly coming from observational data, right?
- 10:10Tor Biering- Sørensen: And we know that that observational data is great, but we can't really be certain about the estimates that we assess in many of these because there are you know still residual confounding.
- 10:25Tor Biering- Sørensen: It depends on which methods you use.
- 10:28Tor Biering- Sørensen: And we can probably only be as certain as we can for a causal relationship if we see similar trends in randomised control trials.
- 10:40Tor Biering- Sørensen: And we in Denmark, as in many other countries, have our nationwide registries, and what we set forth to do five years ago was to try to use our nationwide registries to collect all the data, just as we use it when we do observational data in Denmark, but try to implement a prospective randomised control experiments.
- 11:06Tor Biering- Sørensen: So, for example, our Dan flu trial, we prospectively individually randomised all Danish citizens that were willing to participate to receive one of two flu vaccines, either high dose or standard dose flu vaccine.
- 11:26Tor Biering- Sørensen: And then we followed them through the registries to see whether there was any differences, you know, leveraging the same registries as we use for our observation data.
- 11:39Tor Biering- Sørensen: But here we have just embedded this prospective randomisation.
- 11:42Tor Biering- Sørensen: So the differences that we see between our two groups, we are certain that it's causally linked to what we've randomised the population to, right?
- 11:51Tor Biering- Sørensen: And we were successful in Danflu, for example, to randomise 332 Danish citizens.
- 11:58Tor Biering- Sørensen: And therefore, the differences that we see in cardiovascular events can only be caused by one group receiving a high dose flu vaccine that we know is more potent, that we know prevents superiorly against the standard dose flu vaccines.
- 12:14Tor Biering- Sørensen: And therefore, using these registry to do these giga vaccine trials, we can really get a more certain estimate of what preventing infections potentially also leads to in downstream events.
- 12:30Tor Biering- Sørensen: And there, for example, we have seen that heart failure hospitalisation within the Dan Flu trial, we saw that heart failure hospitalisation, risk of heart failure hospitalisation was lowered with 20% in those who were randomised to the high dose flu vaccine versus the standard dose flu vaccine, giving us a causal insight into preventing flu may also lead to preventing heart failure.
- 13:01Tor Biering- Sørensen: And I think you know even the subgroups within these giga trials are larger than the largest randomised control evidence that has been conducted within, let's say, diabetes.
- 13:14Tor Biering- Sørensen: We had 40,000 individuals with diabetes in Danflu.
- 13:18Tor Biering- Sørensen: You know, a vaccine trial of that magnitude within diabetes has never been conducted and will never be conducted before, right?
- 13:27Tor Biering- Sørensen: So even the subgroups of these many diseases are larger than the largest randomized evidence that we have until now.
- 13:36Tor Biering- Sørensen: So we can really leverage this these giga trials to assess the topic that we're discussing here today, these downstream events and also how these subgroups have higher risk of infections.
- 13:50Tor Biering- Sørensen: And we see, as we also knew from the observation data, that if you have diabetes, if you have cardiovascular disease, your risk of getting infections is much higher than if you don't have, underscoring the fact that we really need to get these high-risk populations vaccinated and protected against infections.
- 14:11Tor Biering- Sørensen: And we also see what we learned from the observation data that these downstream events become deteriorated if you get an infection, and you can see the novel cardiovascular disease in patients or in participants or just in citizens who don't have a cardiovascular disease if they get infection.
- 14:35Tor Biering- Sørensen: So I think they give us additional insights to what we already knew from our observational data, and just add how big is the magnitude of potential prevention if we potentially prevent infections.
- 14:52Jane Barratt (Host): You know, it's an extraordinary set of studies, and I could see Marco nodding.
- 14:58Jane Barratt (Host): The downstream effects that I'm seeing is the public health power, the economic return on investment for these kinds of studies, which is absolutely extraordinary.
- 15:10Jane Barratt (Host): So thank you, for explaining that so well.
- 15:15Jane Barratt (Host): I'd just like to also introduce Dr.
- 15:17Jane Barratt (Host): Kirsty Short.
- 15:18Jane Barratt (Host): She's an MH and NH and MRC Research Fellow and head of the Viral Pathogenesis Lab at the School of Chemistry and Molecular Biosciences at the University of Queensland.
- 15:30Jane Barratt (Host): She leads the Viral Pathogenesis Laboratory, and her research focuses on how chronic metabolic conditions such as diabetes and obesity shape the severity of influenza and SARS-CoV-2, as well as on emerging viruses and pandemic preparedness.
- 15:48Jane Barratt (Host): It's good to have you with us, Kirsty.
- 15:51Kirsty Short: Thank you.
- 15:53Jane Barratt (Host): I just wanted to touch on just very briefly, you know, we're talking about this collision of infections and chronic disease.
- 16:04Jane Barratt (Host): And just wondering your thoughts about what's the biggest misconceptions that are continuing to hold back progress in this whole field of study?
- 16:16Kirsty Short: I think there's a few things.
- 16:18Kirsty Short: And some of this is changing.
- 16:20Kirsty Short: So when I first got into this field and looking at the role of diabetes in susceptibility to viral infections, I would talk to endocrinologists, and endocrinologists would say, Well, yes, you know, this is a problem, but people living with diabetes have so many other things to deal with.
- 16:40Kirsty Short: This is just really low on the low priority list.
- 16:43Kirsty Short: And I think that actually changed with COVID because I think we realised actually that this susceptibility factor has real-world implications, and especially in the context of a pandemic.
- 16:54Kirsty Short: So I think that's one of the things that we've seen the field shift.
- 16:59Kirsty Short: I think the other thing that we're really now seeing a shift in the field is the bidirectional nature of these interactions, whereby we know that diabetes and obesity increases the risk of severe COVID, severe flu.
- 17:16Kirsty Short: But now we're appreciating, and especially with the field of long COVID, that actually things like SARS-CoV-2 can actually trigger the onset of diabetes.
- 17:25Kirsty Short: And so I think it's really this bi-directional relationship that we're only just starting to appreciate.
- 17:32Marco Goeijenbier: Yeah, to respond to that, Kirsty, I think you're you're absolutely right.
- 17:35Marco Goeijenbier: And the pandemic helped there a bit.
- 17:37Marco Goeijenbier: We also discussed it earlier with Tor.
- 17:40Marco Goeijenbier: But already now, I mean, we're even not that far away from the pandemic yet, but already the focus is already losing a bit from the sub-specialties, that they don't have a lot of time, and their patient group, they have a lot of problems talking about persons living with diabetes or cancer or any on, and you only have much time to talk to your patient.
- 18:00Marco Goeijenbier: And while the pandemic helped for a bit, I think already now the interest is already moving a bit towards the back.
- 18:10Jane Barratt (Host): And that's why IDC is so important, you know, because you've got 25 organisations coming together across sectors and across disciplines.
- 18:19Jane Barratt (Host): So, Marco, I'm interested to understand how we can translate these ambitions into measurable change in the next two or three years.
- 18:29Jane Barratt (Host): That's a big lift for a relatively small organisation.
- 18:34Jane Barratt (Host): What are your thoughts about that?
- 18:37Marco Goeijenbier: it's starting with things like this, like this podcast, and combining the great work Thor is doing with his gigantic trials, and on the same end, the work Kirsty's already been doing for 10, 15 years, where she really combines the in vitro with in vivo data.
- 18:57Marco Goeijenbier: So really both using the lab and clinical samples to prove this bidirectional relationship.
- 19:05Marco Goeijenbier: And while indeed showing that specific patient group have a higher chance of a more severe course of infection, I think the other way around, the other part of the medal, the bidirectional one, is the one we should focus on now because I think that could use lots more of attention.
- 19:21Marco Goeijenbier: Well, for instance, the cardiologist did a great job, past couple of years.
- 19:25Marco Goeijenbier: I think there have been quite some big cardio conferences that really focused on flu or on vaccination as a role of prevention.
- 19:33Marco Goeijenbier: We should really see this collaborative effort of the IDC to combine our knowledge, but also to look into to success stories and really really tell this story about the IDC and how to increase prevention.
- 19:48Jane Barratt (Host): Yeah, it's a very ambitious program.
- 19:51Jane Barratt (Host): Bringing different organisations, to the table with a common agenda.
- 19:58Jane Barratt (Host): S o I'm interested in, and we say it all the time, how do you break the silos?
- 20:06Jane Barratt (Host): You know, what's your techniques in actually getting everybody to the table and being able to have a common agenda?
- 20:13Jane Barratt (Host): Because that's what we need.
- 20:15Jane Barratt (Host): That's you know, somewhat of what happened in the pandemic, but that's what we need IDC to do.
- 20:22Jane Barratt (Host): So Tor, you were nodding when I said that.
- 20:25Jane Barratt (Host): So do you have any thoughts about how to bring these organisations to the table?
- 20:31Tor Biering- Sørensen: I think it's always hard to break down, silos.
- 20:35Tor Biering- Sørensen: And we unfortunately as specialists, Marco and I, work in different specialities.
- 20:43Tor Biering- Sørensen: But and it's always you know hard to get you know cardiologists, diabetologists, intensive care physicians to work on the same team because we care so much about our own organs and our own specialities, right?
- 21:04Tor Biering- Sørensen: But I think spreading the word and again as we discussed earlier and as Kirsty also mentioned, we really have this unique opportunity because of the pandemic, because there all specialities came to the table and viewed one infection as a very important case for all specialities.
- 21:28Tor Biering- Sørensen: In Denmark, all specialities did research in COVID in that period and all around the world we could see that regardless which kind of specialty you came from, the publications on COVID increased exponentially, of course.
- 21:49Tor Biering- Sørensen: But Mark was also right that we only have this very short time span after the pandemic to keep this interest because I can also see that it's decreasing and it's decreasing at a quite high pace.
- 22:05Tor Biering- Sørensen: I can also see it in the vaccine uptake rates in Denmark that are also now decreasing after the pandemic.
- 22:12Tor Biering- Sørensen: I think the we really need to leverage this time uh point we have now and to spread the word.
- 22:21Tor Biering- Sørensen: And I think this initiative, of course, and also you know, the more that we as researchers, all of us are academics and researchers, can spread the word within the different specialties and hopefully increase the awareness by symposia, by you know, making sure that we are present scientifically and academically at as many meetings as possible.
- 22:49Tor Biering- Sørensen: Me, myself, we are, you know, all my fellows are cardiologists, but we for the first time now are submitting, you know, abstracts to thetherapeutic meeting, to the diabetes meeting, to the...
- 23:02Tor Biering- Sørensen: because when we do research within infections and how they affect these other specialities, as mentioned, the subgroups within these, you know, these trials that we do are larger and provides the largest randomized evidence.
- 23:20Tor Biering- Sørensen: So, you know, we academically should also do whatever we can to keep on providing science, doing research that spans broadly and not only within our own specialty.
- 23:37Tor Biering- Sørensen: And I know that Marco, Kirsty, and I do whatever we can also, you know, to back up this with hardcore science.
- 23:46Tor Biering- Sørensen: but it is a hard job, Jane, and I agree completely that I probably haven't come up with the answer.
- 23:55Tor Biering- Sørensen: I don't know whether Marco or Kirsty have better answers to figure out how to break down these silos.
- 24:01Jane Barratt (Host): What you've demonstrated, Tor in your words and in practice, as has Marco and Kirsty, is that your leadership, you know, you are reaching out across disciplines and sectors to bring people to the table because you have that, small window of opportunity.
- 24:18Jane Barratt (Host): Kirsty, looking ahead to 2026 and beyond, I'd be very interested in your thoughts about what are the most urgent scientific and clinical questions the IDC must confront next.
- 24:31Kirsty Short: I think there's a lot, and that's one of the reasons it's great to have the IDC.
- 24:35Kirsty Short: I think top of my list is really looking at how these acute viruses cause long-term complications, and in particular, long-term complications like metabolic disease, because I think we've only just scratched the surface of that when we talk about long COVID.
- 24:54Kirsty Short: But of course, we know that other viruses can have these long-term effects as well.
- 24:59Kirsty Short: There's actually very good evidence from past flu pandemics of long flu.
- 25:04Kirsty Short: So, what's flu doing?
- 25:06Kirsty Short: Is flu having implications on metabolic disease like what we've seen with COVID?
- 25:10Kirsty Short: Is that more prevalent in some individuals?
- 25:13Kirsty Short: Why is obesity in itself a risk factor for these long-term complications?
- 25:19Kirsty Short: There's all these sorts of questions that I think we need to answer.
- 25:23Kirsty Short: And these long-term complications of viral infections and the implication for non-communicable disease, I think is really, really important because when you look at most countries' pandemic preparedness plans and their plans for COVID, everything was focused on the acute disease.
- 25:43Kirsty Short: Minimise the severity of the acute disease.
- 25:45Kirsty Short: And that's of course very, very important.
- 25:47Kirsty Short: But what we know now is it's not just about the acute disease, it's also about the long-term consequences of the disease.
- 25:54Kirsty Short: So I think if we can really work very hard to sort of nut this out, this is something that could ultimately get integrated into pandemic preparedness planning such that when the next pandemic comes, we are preparing our healthcare system not just for the acute disease, but also the rise in non-communicable diseases as a result of the viral infection.
- 26:20Jane Barratt (Host): As we start wrapping up this podcast, I want to come to each of you and ask you for your closing statement to the audience, because your voices are important to ensure that the message about IDC, what you do, how you do it, and why you do it is disseminated, throughout the world.
- 26:42Jane Barratt (Host): And so I'll start off with you, Tor, and then go to Kirsty and Marco.
- 26:47Jane Barratt (Host): So what do you want the audience to hear, Tor?
- 26:50Tor Biering- Sørensen: I'm a cardiologist.
- 26:52Tor Biering- Sørensen: I've been just like we discussed, focusing on the cardiac conditions.
- 26:57Tor Biering- Sørensen: But what I've learned over the last couple of years doing these trials, we just as Kirsty and Marco knew much earlier than I knew, that we see in our randomised trials that patients with a broad range of comorbidities, both within my own field cardiovascular, but also diabetes and other non-communicable diseases, they are in much, much higher risk of having a severe infection that leads to hospitalisation.
- 27:35Tor Biering- Sørensen: We only in our trial measure hospitalisation events because we designed our trials to assess these heart events, and we see that they have much, much higher rates.
- 27:45Tor Biering- Sørensen: So despite the fact that a vaccine effectiveness might be the same, spanning, you know, that it's not we don't see a higher vaccine effectiveness in these populations, the absolute numbers that you prevent of hospitalisation is much greater just because the event rate, baseline event rate is much, much higher in these groups, underscoring the importance of prioritising to make sure that that these patients get vaccinated.
- 28:14Tor Biering- Sørensen: And I think that's probably the most important thing that I have observed that we don't see a greater effect of the vaccine, but just the similar effect in a high-risk population with diabetes or chronic cardiovascular disease, they have a much higher risk.
- 28:30Tor Biering- Sørensen: So getting them vaccinated means that you're preventing an absolute greater number of hospitalisation events, underscoring the importance of thinking of vaccinating and getting these inhabitants vaccinated is extremely important.
- 28:48Jane Barratt (Host): And as we've talked about the downstream consequences, you know, to public health, but also to the economy.
- 28:55Jane Barratt (Host): Kirsty, your takeaway message.
- 28:58Kirsty Short: I think my takeaway message is that viruses are tricky.
- 29:01Kirsty Short: We think that one virus will infect people across the board and it will be the same.
- 29:08Kirsty Short: And it's certainly not that.
- 29:10Kirsty Short: We know now that one of the major outcomes in determining disease severity is whether or not you have one or more of these comorbidities and in particular things like diabetes and obesity.
- 29:22Kirsty Short: But the trickiness of virus doesn't end there.
- 29:27Kirsty Short: They're tricky as well because they don't just cause acute disease, they can also cause long-term disease.
- 29:33Kirsty Short: And some of this long-term disease results in non-communicable complications.
- 29:38Kirsty Short: So, like the link between SARS-CoV-2 infection and the onset of diabetes.
- 29:43Kirsty Short: We also now know that viruses can interact with other non-communicable diseases like cancer, and things like the SARS-CoV-2 vaccine is actually beneficial in the context of cancer, as well as some viral infections exacerbating cancer growth and metastases.
- 30:03Kirsty Short: So, my take-home message is we can't just assume viruses because they're these simple non-living organisms, just infect, are cleared and are done.
- 30:15Kirsty Short: It's so much more complicated than that.
- 30:17Kirsty Short: And it interacts across so many different fields and aspects of your health.
- 30:22Jane Barratt (Host): Thank you very much, Kirsty.
- 30:24Jane Barratt (Host): And I will never forget that viruses are tricky.
- 30:27Jane Barratt (Host): So it's a great catch line.
- 30:30Jane Barratt (Host): So thank you for that.
- 30:31Jane Barratt (Host): Marco.
- 30:33Marco Goeijenbier: It's almost a shame to add something after that because it's such a good summary of what we're telling here.
- 30:38Marco Goeijenbier: I think I would like to add two points.
- 30:41Marco Goeijenbier: And I think the first thing is it will be really saw during the pandemic, and in certain countries in the world worked really, really well.
- 30:49Marco Goeijenbier: Is that only to truly prevent tricky things such as viruses or infectious diseases, we really need to work together across all disciplines.
- 30:57Marco Goeijenbier: Because we need indeed the basic scientists proving that the vaccine works, and we need the big trials to prove that the vaccines are effective.
- 31:07Marco Goeijenbier: But we also need to get the vaccines in the arm of the patient.
- 31:10Marco Goeijenbier: And that's really, really tricky also with the continuous growth of vaccination vaccine hesitancy, also logistics, economy, and so on.
- 31:21Marco Goeijenbier: And why it's so important to really work across all these disciplines is that with the population only getting older and older, and the number of comorbidities growing within these elderly patients, and we need to keep healthcare payable, the economic reasons are really a big thing there.
- 31:41Marco Goeijenbier: I think vaccination is such an effective and relatively cheap intervention that would definitely be cost effective.
- 31:49Marco Goeijenbier: so then again, my closing remark is the only thing to really reach that goal and to increase vaccination coverage is really if we if we work all together from all different disciplines.
- 32:01Jane Barratt (Host): I've had the great opportunity today to be inspired by three leaders of our time, Marco, Tor, and Kirsty.
- 32:09Jane Barratt (Host): Thank you for your insights and for your leadership and for continuing to bring to this work to the world.
- 32:16Jane Barratt (Host): Thank you to our listeners for joining us for this episode of ESWI Airborne.
- 32:21Jane Barratt (Host): To learn more about the Interdisciplinary Disease Collaboration on Respiratory Infections and NCDs, please follow our activities and visit ESWI.org.
- 32:32Jane Barratt (Host): Thank you very much.
- 32:40ESWI Secretariat: ESWI Airborne is brought to you by ESWI, the European Scientific Working Group on Influenza and other acute respiratory viruses.
- 32:48ESWI Secretariat: These episodes would not be possible without the team's efforts, and we would like to extend special thanks to our ESWI Secretariat, our technical and IT teams, our arts team, and our host Jane Barrett.
- 33:01ESWI Secretariat: The podcasts are recorded virtually, and we thank our guests for their participation in this inspiring series.
- 33:08ESWI Secretariat: Talks are adapted to a global audience and are intended to be educational.
- 33:12ESWI Secretariat: For any specific medical questions you may have, these should be addressed to your local general practitioner.
- 33:18ESWI Secretariat: Many thanks to our sponsoring partners, and thank you for listening.